Fundraising FoxIllumina Ventures — 2021 Investments
7 investments dated 2021 · listed companies and verified rows first · show all
RedShiftBio develops analytical technology that provides real-time measurement of biomolecular structure and concentration, aimed at supporting decisions in biopharmaceutical development and manufacturing.
BiotechDeep TechHardwareBoxborough, US
Thomas O'Lenic(Executive Officer, Director)Eugene Ma(Executive Officer)Charles Marshall(Executive Officer, Director)
BoardFrank Smith(Director)inWilliam Cadogan(Director)Bryson Hollimon(Director)
Co-investorsTechnology Venture Partners
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)inSteve Chen(Co-founder, COO and Director)inYiyuan Yin(Co-founder, VP of Technology)inTod White(President)inJustin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsQiming Venture PartnersSamsara BioCapital
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.
BiotechDigital HealthHealthtechSouth San Francisco, US
Lisa Alderson(Executive Officer, Director)inRandal Scott(Director)Jill Davies(Executive Officer, Director)inElizabeth Moreno(Executive Officer)inMark Sylvester(Chief Financial Officer)inAndrew Warner(Vice President, Product)in
Co-investorsAlumni VenturesAvestria VenturesCanaan PartnersDreamers VCEcho Health VenturesGV (Google Ventures)+11 more
BiotechCambridge, US
Shawn Marcell(Executive Officer, Director)Ben Linden(Executive Officer)inDavid Yu Zhang(Director)Peng Yin(Director)
BoardAdam Wiechhaus(Director)
Co-investorsNorthpond Ventures
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Co-investorsARCH Venture PartnersM VenturesNorthpond VenturesNovalis LifeSciences
Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
Lewis Williams(Co-founder & CEO)inRusty Williams(Founder)Antonin de Fougerolles(Director)Momo Wu(Director)Stella Xu(Director)Alexis Ji(Director)
Co-investorsFirst Spark Ventures, LlcPandect BioventuresNorthpond Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.